Adagio Medical Expands Use of ULTA Technology in Critical Cardiac Cases — Adagio Medical Holdings, Inc.

Event summary

Adagio Medical completed 13 ventricular ablation procedures using its ULTA technology under FDA Expanded Access authorization.
Procedures targeted recurrent ventricular tachycardia (VT) and premature ventricular contractions (PVCs) in patients who failed prior ablation treatments.
Dr. Gregory Supple of the Hospital of University of Pennsylvania highlighted ULTA's advantages in treating challenging cases near coronary arteries.
Adagio aims to present FULCRUM-VT trial results at the Heart Rhythm Society meeting in April 2026.
The company expects FDA approval for its vCLAS Cryoablation System by year-end 2026.

The big picture

Adagio Medical is positioning its ULTA technology as a differentiated solution for complex cardiac arrhythmias, particularly in cases where traditional ablation methods fail. The FDA's Expanded Access authorization highlights both the unmet clinical need and the potential regulatory flexibility for innovative technologies. With PVC ablations representing roughly 50% of the VT ablation market, Adagio's success in this area could significantly expand its addressable market if regulatory approval is achieved.

What we're watching

Regulatory Pathway: Whether the FDA's Expanded Access cases will accelerate ULTA technology's approval timeline beyond year-end 2026.
Market Expansion: How Adagio's success in treating PVCs could unlock half of the VT ablation market, currently without FDA-approved solutions.
Clinical Validation: The pace at which Adagio can publish and disseminate FULCRUM-VT trial results to bolster its regulatory and commercial position.